Evidence map›Paper›PMID 34107856›Full record

ArticleBioengineered2021

Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment.

Linying Wei, Jianyang Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. LncRNA CASC19: a novel oncogene involved in human cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Linying WeiDepartment of Respiratory and Critical Care Medicine, People's Hospital of Changshan, Quzhou City, Zhejiang Province, China.ORCID 0000-0002-0961-3618
Jianyang JiangDepartment of Respiratory and Critical Care Medicine, People's Hospital of Quzhou, Quzhou City, Zhejiang Province, China.
Hunan Provincial People's Hospital · CNQuzhou City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unclear pathogenesis mechanisms and resistance of cancer cells to chemical drugs serious limits the development of effective treatment strategies for non-small cell lung cancer (NSCLC). In this study, we managed to investigate this issue, and identify potential cancer associated biomarkers for NSCLC diagnosis, prognosis and treatment. This study found that miR-6734-3p was downregulated in both NSCLC clinical specimens (tissues and serum) and cells, compared to the normal tissues and cells. Next, upregulation of miR-6734-3p inhibited cancer formation and progression in NSCLC cells

Indexed as

Base SequenceCarcinoma, Non-Small-Cell LungCell Line, TumorCisplatinDisease ProgressionDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansLung NeoplasmsMicroRNAsPhenotypeProteolysisSignal TransductionZinc Finger E-box Binding Homeobox 2CisplatinMicroRNAsMIRN6734 microRNA, humanZinc Finger E-box Binding Homeobox 2chemosensitivitycisplatinmiR-6734-3pNon-small cell lung cancerzinc finger E-box binding homeobox 2

Identifiers

PMID34107856
PMCPMC8806905
OpenAlexW3170875375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.